Mineralys Therapeutics Inc.
MLYS | NASDAQ
$28.31
+$0.29 (+1.03%)
At close: Sep 21, 2026, 4:00 PM ET
$28.35
+$0.04 (+0.14%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -170.6M | -192.4M | -84.66M | -31.48M | -18.73M | -2.94M |
Interest Income | 15.95M | 14.59M | 12.76M | 1.68M | n/a | n/a |
Pretax Income | -154.65M | -177.81M | -71.9M | -29.8M | -19.41M | -3.43M |
Net Income | -154.65M | -177.81M | -71.9M | -29.8M | -19.41M | -3.43M |
Selling & General & Admin | 38.6M | 23.82M | 14.3M | 5.23M | 2.42M | 532K |
Research & Development | 132.01M | 168.58M | 70.36M | 26.25M | 16.31M | 2.41M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 170.6M | 192.4M | 84.66M | 31.48M | 18.73M | 2.94M |
Interest Expense | n/a | n/a | n/a | 1.68M | 27K | 115K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 170.6M | 192.4M | 84.66M | 31.48M | 18.73M | 2.94M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 67.66M | 48.54M | 36.19M | 5.17M | 4.98M | 4.63M |
Shares Outstanding (Diluted) | 67.66M | 48.54M | 36.19M | 5.17M | 4.98M | 4.63M |
EPS (Basic) | -2.29 | -3.66 | -1.99 | -5.77 | -3.89 | -0.74 |
EPS (Diluted) | -2.29 | -3.66 | -1.99 | -5.77 | -3.89 | -0.74 |
EBITDA | -154.59M | -177.77M | -71.9M | -28.12M | -19.38M | -3.31M |
EBIT | -154.65M | -177.81M | -71.9M | -28.12M | -19.38M | -3.31M |
Depreciation & Amortization | 59K | 43K | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove MLYS